Key result
Treatment with the MEK1/2 inhibitor U0126 from 6 to 24 hours after subarachnoid hemorrhage completely prevented delayed vasoconstrictor receptor upregulation and improved neurological outcome in rats.
Why the study?
Does the duration of acute CBF drop or early MEK-ERK1/2 inhibition affect delayed vasoconstrictor receptor upregulation and cerebral ischemia in a rat SAH model?
Does the duration of acute CBF drop or early MEK-ERK1/2 inhibition affect delayed vasoconstrictor receptor upregulation and cerebral ischemia in a rat SAH model?
The duration of acute cerebral blood flow drop after subarachnoid hemorrhage triggers MEK-ERK1/2 activation and subsequent delayed vasoconstrictor receptor upregulation, which can be prevented by early MEK1/2 inhibition.
Early MEK1/2 inhibition may improve experimental SAH outcomes; hypothesis-generating and requires clinical validation before practice change.
BACKGROUND: Upregulation of vasoconstrictor receptors in cerebral arteries, including endothelin B (ETB) and 5-hydroxytryptamine 1B (5-HT(1B)) receptors, has been suggested to contribute to delayed cerebral ischemia, a feared complication after subarachnoid hemorrhage (SAH). This receptor upregulation has been shown to be mediated by intracellular signalling via the mitogen activated protein kinase kinase (MEK1/2)--extracellular regulated kinase 1/2 (ERK1/2) pathway. However, it is not known what event(s) that trigger MEK-ERK1/2 activation and vasoconstrictor receptor upregulation after SAH.We hypothesise that the drop in cerebral blood flow (CBF) and wall tension experienced by cerebral arteries in acute SAH is a key triggering event. We here investigate the importance of the duration of this acute CBF drop in a rat SAH model in which a fixed amount of blood is injected into the prechiasmatic cistern either at a high rate resulting in a short acute CBF drop or at a slower rate resulting in a prolonged acute CBF drop. RESULTS: We demonstrate that the duration of the acute CBF drop is determining for a) degree of early ERK1/2 activation in cerebral arteries, b) delayed upregulation of vasoconstrictor receptors in cerebral arteries and c) delayed CBF reduction, neurological deficits and mortality. Moreover, treatment with an inhibitor of MEK-ERK1/2 signalling during an early time window from 6 to 24 h after SAH was sufficient to completely prevent delayed vasoconstrictor receptor upregulation and improve neurological outcome several days after the SAH. CONCLUSIONS: Our findings suggest a series of events where 1) the acute CBF drop triggers early MEK-ERK1/2 activation, which 2) triggers the transcriptional upregulation of vasoconstrictor receptors in cerebral arteries during the following days, where 3) the resulting enhanced cerebrovascular contractility contribute to delayed cerebral ischemia.
No takes yet. Share an insight, caveat, or question.
Povlsen et al. (2013) studied Subarachnoid hemorrhage (n=79). U0126 (MEK1/2 inhibitor) vs. Vehicle (isotonic saline plus 0.1% DMSO) was evaluated on Delayed upregulation of vasoconstrictor receptors and neurological deficits. Treatment with the MEK1/2 inhibitor U0126 from 6 to 24 hours after subarachnoid hemorrhage completely prevented delayed vasoconstrictor receptor upregulation and improved neurological outcome in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: